AN ASIAN, PHASE 2, MULTICENTER, RANDOMIZED,DOUBLE-BLIND, PLACEBO- AND PREGABALIN-CONTROLLED,DOSE-FINDING STUDY OF DS-5565 IN PATIENTS WITH PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Mirogabalin (Primary) ; Pregabalin
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Mar 2013 Planned end date changed from 1 Apr 2013 to 31 May 2013 as reported by Korean Clinical Trials Register record.